Login to Your Account

SuperGen Merges with Astex in $120M Cash, Stock deal

By Nuala Moran

Friday, April 8, 2011
LONDON – Cancer specialist SuperGen Inc., is taking over its privately held counterpart, Astex Therapeutics plc, in a cash and shares deal, which creates a specialist Anglo-American oncology company with a portfolio of seven drugs in clinical development, $50 million per annum in revenues, $120 million in cash and several high-profile pharma partnerships including three partnered programs in the clinic.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription